Welcome to our dedicated page for Immunovant SEC filings (Ticker: IMVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Immunovant鈥檚 journey from discovery to late-stage trials means wading through pages of scientific jargon and cash-flow tables. The latest annual report details anti-FcRn antibody engineering, while every 8-K discloses clinical milestones that can move the share price overnight. If you have ever typed 鈥淚mmunovant SEC filings explained simply鈥� or 鈥淗ow do I read Immunovant鈥檚 quarterly earnings report 10-Q filing?鈥� you know the challenge.
Stock Titan鈥檚 AI-powered analysis turns each document into clear, skimmable insights. Our platform highlights where the 10-K reveals batoclimab safety data, flags liquidity risks inside the 10-Q, and alerts you to 鈥淚mmunovant insider trading Form 4 transactions鈥� the moment they post to EDGAR. Need 鈥淚mmunovant 8-K material events explained鈥�? We annotate trial updates line-by-line, while real-time push notices track 鈥淚mmunovant Form 4 insider transactions real-time鈥� and upcoming votes on executive pay.
- AI summaries of every Immunovant annual report 10-K simplified
- Side-by-side comparisons across sequential 10-Q filings
- Instant alerts for insider buys, sells, and option grants
Whether you monitor R&D spend, compare pipeline timelines, or follow 鈥淚mmunovant proxy statement executive compensation,鈥� all filings are one click away. Use our technology for 鈥淚mmunovant earnings report filing analysis,鈥� dive deep into cash runway tables, or export Form 4 data on 鈥淚mmunovant executive stock transactions Form 4.鈥� Professional investors rely on Stock Titan to surface hidden details fast鈥攕o you can act on information, not search for it.
Immunovant is a clinical-stage immunology company advancing two anti-FcRn antibodies, IMVT-1402 and batoclimab. For the quarter ended June 30, 2025 the company reported a net loss of $120.6 million versus $87.2 million a year earlier, driven by higher research and development ($101.2 million versus $75.5 million) and increased general and administrative expense ($26.0 million versus $18.8 million). Cash and cash equivalents totaled $598.9 million at quarter end, down from $714.0 million three months earlier, and cash used in operations was $117.4 million.
The company has initiated multiple potentially registrational IMVT-1402 trials across Graves disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis, Sj f6grens disease and a CLE proof-of-concept study, and expects a Graves disease readout in 2027. Batoclimab Phase 3 top-line results in thyroid eye disease are expected in the second half of 2025. Contractual commitments include an estimated $43.1 million remaining minimum purchase obligation to Samsung and potential milestone payments under the HanAll license up to $420.0 million (after $32.5 million previously paid).
FAQ
What is the current stock price of Immunovant (IMVT)?
What is the market cap of Immunovant (IMVT)?
